采用尿液LC-MS/MS评估2型糖尿病中心血管代谢药物不依从性及其与肾脏和心血管结局的关联
这项队列研究纳入1125例来自PROVALID研究的2型糖尿病患者,采用尿液LC-MS/MS直接检测79种心血管代谢药物及其代谢物以评估不依从性。中位随访5.10年发现,抗血小板药物不依从者心血管结局更差(HR 10.13),降压药不依从者肾脏结局更差(HR 1.98)。
要点
- 56.3%完全依从,42.0%部分不依从,1.7%完全不依从于所筛查的心血管代谢药物。
- 抗血小板药物不依从与更差的心血管结局相关(HR 10.13,95%CI 3.06-33.56)。
- 降压药物不依从与更差的肾脏结局相关(HR 1.98,95%CI 1.37-2.86)。
核心结论
- 本分析显示,2型糖尿病患者中心血管代谢药物方案不依从现象常见,并对肾脏和心血管结局产生负面影响。
研究设计与样本
- 本队列研究纳入来自PROVALID研究的1125例在初级保健层面随访的2型糖尿病患者。
- 采用LC-MS/MS检测基线尿液样本中79种心血管代谢药物及其代谢物,以直接、客观评估不依从性。
主要发现
- 56.3%的参与者完全依从,42.0%部分不依从,1.7%完全不依从于所筛查的心血管代谢药物。
- 对抗血小板药物和降糖药物的依从性最高,对他汀类降脂药物的依从性最低。
- 中位(IQR)随访5.10(4.12-6.12)年,抗血小板药物不依从者心血管结局更差(HR 10.13,95%CI 3.06-33.56)。
- 中位(IQR)随访5.10(4.12-6.12)年,降压药物不依从者肾脏结局更差(HR 1.98,95%CI 1.37-2.86)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Non-adherence to medication is a frequent barrier in the treatment of patients with type 2 diabetes mellitus, potentially limiting the effectiveness of evidence-based treatments. Previous studies have mostly relied on indirect adherence measures to analyse outcomes based on adherence. The aim of this study was to use LC-MS/MS in urine-a non-invasive, direct and objective measure-to assess non-adherence to cardiometabolic drugs and analyse its association with kidney and cardiovascular outcomes. METHODS: This cohort study includes 1125 participants from the PROVALID study, which follows patients with type 2 diabetes mellitus at the primary care level. Baseline urine samples were tested for 79 cardiometabolic drugs and metabolites thereof via LC-MS/MS. An individual was classified as totally adherent if markers for all drugs were detected, partially non-adherent when at least one marker for one drug was detected, and totally non-adherent if no markers for any drugs were detected. Non-adherence was then analysed in the context of cardiovascular (composite of myocardial infarction, stroke and cardiovascular death) and kidney (composite of sustained 40% decline in eGFR, sustained progression of albuminuria, kidney replacement therapy and death from kidney failure) outcomes. RESULTS: Of the participants, 56.3% were totally adherent, 42.0% were partially non-adherent, and 1.7% were totally non-adherent to screened cardiometabolic drugs. Adherence was highest to antiplatelet and glucose-lowering agents and lowest to lipid-lowering agents. Over a median (IQR) follow-up time of 5.10 (4.12-6.12) years, worse cardiovascular outcomes were observed with non-adherence to antiplatelet drugs (HR 10.13 [95% CI 3.06, 33.56]) and worse kidney outcomes were observed with non-adherence to antihypertensive drugs (HR 1.98 [95% CI 1.37, 2.86]). CONCLUSIONS/INTERPRETATION: This analysis shows that non-adherence to cardiometabolic drug regimens is common in type 2 diabetes mellitus and negatively affects kidney and cardiovascular outcomes.
引用
- Denicolò S, Reinstadler V, Keller F, et al. Non-adherence to cardiometabolic medication as assessed by LC-MS/MS in urine and its association with kidney and cardiovascular outcomes in type 2 diabetes mellitus. Diabetologia. 2024. PMID: 38647650. doi:10.1007/s00125-024-06149-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。